{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Salivary+Gland+Tumor&page=6",
    "query": {
      "condition": "Salivary Gland Tumor",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 238,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Salivary+Gland+Tumor&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Salivary+Gland+Tumor&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T19:50:17.337Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02538510",
      "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Nasopharynx Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary",
        "Stage III Major Salivary Gland Carcinoma",
        "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage III Nasopharyngeal Carcinoma",
        "Stage IV Nasopharyngeal Carcinoma",
        "Stage IVA Major Salivary Gland Carcinoma",
        "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVB Major Salivary Gland Carcinoma",
        "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVC Major Salivary Gland Carcinoma",
        "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-10-08",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02538510"
    },
    {
      "nct_id": "NCT00840814",
      "title": "Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Lymphedema"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2008-05",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00840814"
    },
    {
      "nct_id": "NCT00052611",
      "title": "Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2002-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00052611"
    },
    {
      "nct_id": "NCT00530049",
      "title": "Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Psychosocial Effects of Cancer and Its Treatment"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1745,
      "start_date": "2007-08-14",
      "completion_date": "2021-12-17",
      "has_results": false,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00530049"
    },
    {
      "nct_id": "NCT02253238",
      "title": "Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Quality of Life Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Management Surveys",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Monitoring Devices",
          "type": "OTHER"
        },
        {
          "name": "Symptoms Surveys",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Device Usability Survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 427,
      "start_date": "2014-01-07",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02253238"
    },
    {
      "nct_id": "NCT03781986",
      "title": "APG-115 in Salivary Gland Cancer Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Salivary Gland Cancer",
        "Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "APG-115",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-10-28",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03781986"
    },
    {
      "nct_id": "NCT04704661",
      "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Advanced Colon Carcinoma",
        "Advanced Colorectal Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Gastric Carcinoma",
        "Advanced Gastroesophageal Junction Adenocarcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Salivary Gland Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "HER2-Positive Breast Carcinoma",
        "Malignant Hepatobiliary Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Colon Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Salivary Gland Carcinoma",
        "Stage III Colon Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Major Salivary Gland Cancer AJCC v8",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Major Salivary Gland Cancer AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Unresectable Breast Carcinoma",
        "Unresectable Colon Carcinoma",
        "Unresectable Colorectal Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Carcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Salivary Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2021-08-09",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 23,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704661"
    },
    {
      "nct_id": "NCT00004163",
      "title": "Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "1999-10",
      "completion_date": "2001-09",
      "has_results": false,
      "last_update_posted_date": "2017-04-18",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 10,
      "location_summary": "New Haven, Connecticut • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hyannis",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004163"
    },
    {
      "nct_id": "NCT00033618",
      "title": "Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Salivary Gland Squamous Cell Carcinoma",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2002-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-27",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033618"
    },
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-10-14T19:50:17.337Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    }
  ]
}